ClinicalTrials.gg
CompletedNCT03971422Updated Aug 20, 2026Results posted

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of Rozanolixizumab and Placebo in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 112 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
Largest of 10
200 · median 67
Started
2019
with 1 other
Phase 3
7 of 10
2 open now
Registered
2nd of 10
by date
Lead sponsor
9 of 10
UCB Biopharma SRL

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one has the largest enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 2nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • UCB7665
  • generalized myasthenia gravis
  • rozanolixizumab
  • gMG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 years of age, at the time of signing the
  • Study participant has documented diagnosis of generalized myasthenia gravis (gMG) at Visit 1, based on study participant's history and supported by previous evaluations
  • Study participant has a confirmed positive record of autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) at Screening (Visit 1).The presence of autoantibodies may be confirmed with repeat testing at Visit 1
  • Study participant has Myasthenia Gravis Foundation of America (MGFA) Class II to IVa at Visit 1
  • Study participant with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of at least 3 (with ≥3 points from non-ocular symptom) AND a quantitative myasthenia gravis (QMG) score of at least 11 at Visit 1 and at Baseline (Visit 2)
  • Study participant is considered for additional treatment such as intravenous immunoglobulin g (IVIg) or plasma exchange (PEX) by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Study participant has a known history of hyperprolinemia
  • Study participant has a active infection (eg, sepsis, pneumonia, or abscess) in the opinion of the Investigator, or had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of medicinal product (IMP)
  • Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous mycobacterial infection (NTMBI) will be excluded
  • Study participant has experienced reaction after exposure to other anti-neonatal Fc receptor (FcRn) drugs
  • Study participant with severe (defined as Grade 3 on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis at Visit 1 or Visit 2
  • Study participant has a history of a solid organ transplant or hematopoietic stem cell/marrow transplant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Dosage Regimen 1

    Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.

    Drug: Rozanolixizumab

  • Experimental
    Dosage Regimen 2

    Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.

    Drug: Rozanolixizumab

  • Placebo comparator
    Placebo

    Study participants randomized to this arm will receive placebo.

    Other: Placebo

Interventions

  • Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

    Also known as: UCB7665

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time points.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement.

    Time frame: Baseline and Day 43

Secondary outcomes

  1. Percentage of Participants Achieving Myasthenia Gravis-Activities of Daily Living (MG-ADL) Response at Day 43

    The MG-ADL is an 8-item PRO instrument developed on the basis of the QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement. Study participants were classified as responders at Day 43 if the value was at least a 2-point improvement (decrease) from Baseline at Day 43.

    Time frame: Day 43

  2. Change From Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) Total Score

    MG-C scale is a validated assessment and scale tests 10 items with individual item being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

    Time frame: Baseline and Day 43

  3. Change From Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) Total Score

    The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement.

    Time frame: Baseline and Day 43

  4. Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score

    MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose response option that how frequently they experienced muscle weakness fatigability (items 34-42) over the past 7 days using a 5-point Likert scale (1="none of the time" to 5="all of the time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

    Time frame: Baseline and Day 43

  5. Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Physical Fatigue' Score

    The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose the response option that how frequently they experienced physical fatigue (items 19-33) over the past 7 days using a 5-point Likert scale (1="none of the time" to 5="all of the time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

    Time frame: Baseline and Day 43

  6. Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Bulbar Symptoms' Score

    The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose response option that best described severity of bulbar muscle weakness (items 6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

    Time frame: Baseline and Day 43

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) up to and including 8 weeks after the last dose.

    Time frame: From Baseline until End of Study Visit (up to Week 14)

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Investigational Medicinal Product (IMP)

    A TEAE is defined as an AE starting on or after the time of first administration of IMP up to and including 8 weeks after the last dose.

    Time frame: From Baseline until End of Study Visit (up to Week 14)

07

Results

Posted Aug 21, 2023

Participant flow

The study started to enroll study participants in Jun 2019 and concluded in Oct 2021.

Participant flow — Overall Study
MilestonePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Started676667
Completed424343
Not completed252324
Withdrew: Lost to follow-up010
Withdrew: Lack of efficacy511
Withdrew: Adverse event, not fatal225
Withdrew: Worsening of mg symptoms142
Withdrew: Roll over to mg0007 (nct04650854)1069
Withdrew: Roll over to mg0004 (nct04124965)786
Withdrew: Due to covid-19 pandemic011

Outcome measures

PrimaryChange From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score

The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score-0.784 ± 0.488-3.370 ± 0.486-3.403 ± 0.494
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -2.586 · 95% CI -4.091 to -1.249Mixed model repeated measure (MMRM) ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -2.619 · 95% CI -3.994 to -1.163MMRM analysis of covariance (ANCOVA) model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryPercentage of Participants Achieving Myasthenia Gravis-Activities of Daily Living (MG-ADL) Response at Day 43

The MG-ADL is an 8-item PRO instrument developed on the basis of the QMG. The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement. Study participants were classified as responders at Day 43 if the value was at least a 2-point improvement (decrease) from Baseline at Day 43.

Time frame:
Day 43
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Myasthenia Gravis-Activities of Daily Living (MG-ADL) Response at Day 43
percentage of participantsPlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants Achieving Myasthenia Gravis-Activities of Daily Living (MG-ADL) Response at Day 4328.468.261.2
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Wald test · p = <0.001 (p-value is nominal. Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Odds ratio (or): 5.765 · 95% CI 2.100 to 14.882The OR of responder rates is estimated and tested between treatment groups using logistic regression model with treatment group, Baseline MG-ADL score and stratification factor (MuSK+ or AChR+). An OR \> 1 favours rozanolixizumab.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Wald test · p = <0.001 (p-value is nominal. Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Odds ratio (or): 4.273 · 95% CI 1.653 to 11.791The OR of responder rates is estimated and tested between treatment groups using logistic regression model with treatment group, Baseline MG-ADL score and stratification factor (MuSK+ or AChR+). An OR \> 1 favours rozanolixizumab.
SecondaryChange From Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) Total Score

MG-C scale is a validated assessment and scale tests 10 items with individual item being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) Total Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) Total Score-2.029 ± 0.917-5.930 ± 0.916-7.554 ± 0.934
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -3.901 · 95% CI -6.634 to -1.245MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -5.525 · 95% CI -8.303 to -2.968MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryChange From Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) Total Score

The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change in the score indicates worsening and a negative change indicates improvement.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) Total Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) Total Score-1.915 ± 0.682-5.398 ± 0.679-6.672 ± 0.692
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -3.483 · 95% CI -5.614 to -1.584MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -4.756 · 95% CI -6.821 to -2.859MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryChange From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score

MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose response option that how frequently they experienced muscle weakness fatigability (items 34-42) over the past 7 days using a 5-point Likert scale (1="none of the time" to 5="all of the time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' Score-10.588 ± 3.034-23.029 ± 3.034-25.751 ± 3.095
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -12.441 · 95% CI -21.804 to -4.089MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -15.163 · 95% CI -23.596 to -6.450MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryChange From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Physical Fatigue' Score

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose the response option that how frequently they experienced physical fatigue (items 19-33) over the past 7 days using a 5-point Likert scale (1="none of the time" to 5="all of the time") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Physical Fatigue' Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Physical Fatigue' Score-10.637 ± 3.051-19.287 ± 3.046-25.459 ± 3.107
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = 0.012 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -8.650 · 95% CI -18.058 to -0.134MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -14.822 · 95% CI -23.759 to -5.936MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryChange From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Bulbar Symptoms' Score

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants were asked to choose response option that best described severity of bulbar muscle weakness (items 6-15) symptoms over past 7 days using a 4-point Likert scale (1="none" to 4="severe") for each item. Sum of each item score is linearly transformed to have all domain scores ranging from 0 to 100. Total score is calculated as: (sum of item scores within the scale)/(raw score range) x (total number of items in the scale)/(number of non-missing items in the scale) x100 and ranged from 0 to 100, where higher scores indicated severe symptoms.

Time frame:
Baseline and Day 43
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Bulbar Symptoms' Score
units on a scalePlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Change From Baseline to Day 43 in the Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Bulbar Symptoms' Score-3.519 ± 2.397-14.839 ± 2.406-14.224 ± 2.464
Statistical analysis
  • Placebo vs Rozanolixizumab ~7 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -11.320 · 95% CI -18.958 to -4.998MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
  • Placebo vs Rozanolixizumab ~10 mg/kg · Lehmacher and Wassmer method · p = <0.001 (Confidence intervals and p-values are based on stage-wise inverse normal combination using the Lehmacher and Wassmer method.) · Ls mean difference: -10.705 · 95% CI -17.787 to -3.998MMRM ANCOVA model included treatment group, Baseline score, region, stratification factor (MuSK+ or AChR+) and treatment group by day (interaction term) as fixed factors and participant as a random effect.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) up to and including 8 weeks after the last dose.

Time frame:
From Baseline until End of Study Visit (up to Week 14)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)455257
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Investigational Medicinal Product (IMP)

A TEAE is defined as an AE starting on or after the time of first administration of IMP up to and including 8 weeks after the last dose.

Time frame:
From Baseline until End of Study Visit (up to Week 14)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Investigational Medicinal Product (IMP)
ParticipantsPlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Investigational Medicinal Product (IMP)224

Adverse events

Collected over From Baseline until End of Study Visit (up to Week 14). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/67 (0%)6/67 (9%)26/67 (38.8%)
Rozanolixizumab ~7 mg/kg0/64 (0%)5/64 (7.8%)40/64 (62.5%)
Rozanolixizumab ~10 mg/kg0/69 (0%)7/69 (10.1%)42/69 (60.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Myasthenia gravis crisisNervous system disorders2/670/640/69
Myasthenia gravisNervous system disorders1/671/642/69
GastritisGastrointestinal disorders0/671/640/69
VomitingGastrointestinal disorders0/671/640/69
ArthralgiaMusculoskeletal and connective tissue disorders0/671/640/69
SeizureNervous system disorders0/671/640/69
Cervical dysplasiaReproductive system and breast disorders0/671/640/69
COVID-19 pneumoniaInfections and infestations1/670/640/69
Thoracic vertebral fractureInjury, poisoning and procedural complications1/670/640/69
Muscular weaknessMusculoskeletal and connective tissue disorders1/670/640/69
Most frequent other events
Most frequent other events
EventPlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
HeadacheNervous system disorders13/6729/6426/69
DiarrhoeaGastrointestinal disorders9/6716/6411/69
PyrexiaGeneral disorders1/678/6414/69
NauseaGastrointestinal disorders5/675/648/69
HypertensionVascular disorders0/675/640/69
NasopharyngitisInfections and infestations3/671/645/69
ArthralgiaMusculoskeletal and connective tissue disorders2/673/645/69
Urinary tract infectionInfections and infestations4/672/642/69
VomitingGastrointestinal disorders1/671/644/69
MyalgiaMusculoskeletal and connective tissue disorders1/672/644/69

Baseline characteristics

Baseline Characteristics refers to the Randomized Set (RS) which consisted of all study participants who were randomized and analyzed according to the treatment assigned instead of the actual treatment received.

Age, Categorical
Age, Categorical(Participants)PlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
<=18 years1001
Between 18 and 65 years504951150
>=65 years16171649
Age, Continuous
Age, Continuous(years)PlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Mean50.4 ± 17.753.2 ± 14.751.9 ± 16.551.8 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Female473935121
Male20273279
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Asian59721
Black1045
Native Hawaiian or other Pacific Islander1001
White464149136
Missing1416737
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Hispanic or Latino55313
Not Hispanic or Latino484758153
Missing1414634
08

Study locations

112 sites
  • Mg0003 50081
    Phoenix, Arizona 85013, United States
  • Mg0003 50082
    Scottsdale, Arizona 85251, United States
  • Mg0003 50072
    Los Angeles, California 90033, United States
  • Mg0003 50092
    Orange, California 92868, United States
  • Mg0003 50097
    San Francisco, California 94109, United States
  • Mg0003 50099
    San Francisco, California 94117, United States
  • Mg0003 50101
    Aurora, Colorado 80045, United States
  • Mg0003 50088
    Washington D.C., District of Columbia 20037, United States
  • Mg0003 50122
    Miami, Florida 33136, United States
  • Mg0003 50120
    Miami, Florida 33144, United States
  • Mg0003 50073
    Tampa, Florida 33612, United States
  • Mg0003 50075
    Augusta, Georgia 30912, United States
  • Mg0003 50323
    Honolulu, Hawaii 96817, United States
  • Mg0003 50109
    Chicago, Illinois 60637, United States
  • Mg0003 50114
    Indianapolis, Indiana 46202, United States
  • Mg0003 50074
    Fairway, Kansas 66205, United States
  • Mg0003 50121
    Lexington, Kentucky 40536, United States
  • Mg0003 50110
    Ann Arbor, Michigan 48109, United States
  • Mg0003 50102
    Detroit, Michigan 48202, United States
  • Mg0003 50104
    Rochester, Minnesota 55905, United States
  • Mg0003 50105
    St Louis, Missouri 63110, United States
  • Mg0003 50077
    New York, New York 10021, United States
  • Mg0003 50117
    Charlotte, North Carolina 28204, United States
  • Mg0003 50086
    Charlotte, North Carolina 28207, United States
  • Mg0003 50090
    Winston-Salem, North Carolina 27157, United States
  • Mg0003 50076
    Columbus, Ohio 43210, United States
  • Mg0003 50096
    Philadelphia, Pennsylvania 19104, United States
  • Mg0003 50089
    Philadelphia, Pennsylvania 19140, United States
  • Mg0003 50084
    Charleston, South Carolina 29425, United States
  • Mg0003 50113
    Houston, Texas 77030, United States
  • Mg0003 40121
    Brussels, Belgium
  • Mg0003 50067
    Calgary, Canada
  • Mg0003 50066
    Montreal, Canada
  • Mg0003 50070
    Québec, Canada
  • Mg0003 50069
    Toronto, Canada
  • Mg0003 40125
    Ostrava, Czechia
  • Mg0003 40124
    Prague, Czechia
  • Mg0003 40128
    Aalborg, Denmark
  • Mg0003 40127
    Aarhus N, Denmark
  • Mg0003 40126
    Copenhagen, Denmark
  • Mg0003 40489
    Odense, Denmark
  • Mg0003 40129
    Bordeaux, France
  • Mg0003 40070
    Clermont-Ferrand, France
  • Mg0003 40512
    Garches, France
  • Mg0003 40510
    Le Kremlin-Bicêtre, France
  • Mg0003 40360
    Limoges, France
  • Mg0003 40426
    Lyon, France
  • Mg0003 40130
    Marseille, France
  • Mg0003 40017
    Nantes, France
  • Mg0003 40132
    Nice, France
  • Mg0003 40133
    Paris, France
  • Mg0003 40131
    Strasbourg, France
  • Mg0003 20160
    Tbilisi, Georgia
  • Mg0003 20161
    Tbilisi, Georgia
  • Mg0003 20163
    Tbilisi, Georgia
  • Mg0003 20165
    Tbilisi, Georgia
  • Mg0003 40134
    Essen, Germany
  • Mg0003 40140
    Göttingen, Germany
  • Mg0003 40135
    Gummersbach, Germany
  • Mg0003 40139
    Jena, Germany
  • Mg0003 40078
    Leipzig, Germany
  • Mg0003 40177
    Münster, Germany
  • Mg0003 40082
    Kistarcsa, Hungary
  • Mg0003 40178
    Nyíregyháza, Hungary
  • Mg0003 40283
    Bologna, Italy
  • Mg0003 40149
    Lazio, Italy
  • Mg0003 40144
    Milan, Italy
  • Mg0003 40307
    Naples, Italy
  • Mg0003 40146
    Pavia, Italy
  • Mg0003 40148
    Roma, Italy
  • Mg0003 40150
    Roma, Italy
  • Mg0003 20035
    Bunkyō City, Japan
  • Mg0003 20068
    Chiba, Japan
  • Mg0003 20078
    Hanamaki-Shi, Japan
  • Mg0003 20079
    Hiroshima, Japan
  • Mg0003 20075
    Kobe, Japan
  • Mg0003 20071
    Nagasaki, Japan
  • Mg0003 20074
    Ōsaka-sayama, Japan
  • Mg0003 20067
    Sapporo, Japan
  • Mg0003 20077
    Sendai, Japan
  • Mg0003 20070
    Shinjuku-Ku, Japan
  • Mg0003 20076
    Shinjuku-Ku, Japan
  • Mg0003 20032
    Suita, Japan
  • Mg0003 40155
    Gdansk, Poland
  • Mg0003 40154
    Lodz, Poland
  • Mg0003 40151
    Lublin, Poland
  • Mg0003 40153
    Poznan, Poland
  • Mg0003 20168
    Krasnoyarsk, Russia
  • Mg0003 20027
    Moscow, Russia
  • Mg0003 20169
    Novosibirsk, Russia
  • Mg0003 20001
    Saint Petersburg, Russia
  • Mg0003 20028
    Saint Petersburg, Russia
  • Mg0003 20029
    Saint Petersburg, Russia
  • Mg0003 20055
    Saint Petersburg, Russia
  • Mg0003 20197
    Samara, Russia
  • Mg0003 40468
    Belgrade, Serbia
  • Mg0003 40467
    Niš, Serbia
  • Mg0003 40159
    Barcelona, Spain
  • Mg0003 40160
    Barcelona, Spain
  • Mg0003 40267
    Barcelona, Spain

Showing the first 100 of 112 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PubMed 37059507 ↗
  • Habib AA, Sacconi S, Antonini G, Cortes-Vicente E, Grosskreutz J, Mahuwala ZK, Mantegazza R, Pascuzzi RM, Utsugisawa K, Vissing J, Vu T, Wiendl H, Boehnlein M, Greve B, Woltering F, Bril V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241273036. doi: 10.1177/17562864241273036. eCollection 2024. PubMed 39297052 ↗
  • Kaminski HJ, Antozzi C, Habib AA, Pascuzzi RM, Sacconi S, Utsugisawa K, Vissing J, Regnault A, Hareendran A, Grimson F, Tarancon T, Bril V; MycarinG study investigators. Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. Eur J Neurol. 2025 Aug;32(8):e70231. doi: 10.1111/ene.70231. PubMed 40755069 ↗
  • Barnett-Tapia C, Cortes Vicente E, Pascuzzi RM, Utsugisawa K, Bloemers J, Grimson F, Tarancon T, Bril V; MycarinG study investigators. Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. J Neurol. 2025 Nov 8;272(12):752. doi: 10.1007/s00415-025-13480-8. PubMed 41205003 ↗
  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Grimson F, Houston N, Kerbusch V, Pulido-Valdeolivas I, Tarancon T, Vissing J. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. Ther Adv Neurol Disord. 2026 Jun 29;19:17562864261458532. doi: 10.1177/17562864261458532. eCollection 2026. PubMed 42388397 ↗
  • Regnault A, Habib AA, Creel K, Kaminski HJ, Morel T. Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol. 2024 Jun 24;15:1368525. doi: 10.3389/fneur.2024.1368525. eCollection 2024. PubMed 38978809 ↗
  • Matic A, Alfaidi N, Bril V. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis. Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1163-1171. doi: 10.1080/14712598.2023.2296126. Epub 2023 Dec 28. PubMed 38099334 ↗
  • Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865. doi: 10.1212/WNL.0000000000011108. Epub 2020 Nov 20. PubMed 33219142 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Aug 2021, 26 months.

Results were first posted in Aug 2023, 1 year 11 months after primary completion. A results delay was requested in Aug 2022.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 26 months is close to that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2019
First posted
Jun 3, 2019
StartActual
Jun 3, 2019
Primary completionActual
Aug 31, 2021
CompletionActual
Oct 26, 2021
Results delay requested
Aug 30, 2022
Results first posted
Aug 21, 2023
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03971422
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
Jun 3, 2019
Primary completion
Aug 31, 2021
Completion
Oct 26, 2021
Results posted
Aug 21, 2023
Last update
Aug 20, 2026

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion